One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients

Lorena Incorvaia, Viviana Bazan, Giuseppe Badalamenti, Antonio Russo, Lorena Incorvaia, Carlo Messina, Antonio Russo, Emmanuela Musso, Alessandra Casarin, Ida De Luca, Maria Rita Ricciardi, Giuseppe Badalamenti, Viviana Bazan, Alessandra Casarin, Emmanuela Musso, Ida De Luca, Maria Rita Ricciardi

Risultato della ricerca: Articlepeer review

5 Citazioni (Scopus)

Abstract

Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT. Methods: We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3. Results: The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%, respectively. The antiemetic regimen was well tolerated. Conclusions: This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy.
Lingua originaleEnglish
Numero di pagine0
RivistaSupportive Care in Cancer
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???

Fingerprint

Entra nei temi di ricerca di 'One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients'. Insieme formano una fingerprint unica.

Cita questo